Abstracts Archive - Page 218 of 2607 - ACR Meeting Abstracts

Abstract Number: 2592 • ACR Convergence 2024
The Effects of Early Life Trauma and Socioeconomic Position on Systemic Lupus Erythematosus Risk in Adulthood
Jennifer Woo¹ and Dale Sandler², ¹Epidemiology Branch, National Institute of Environmental Health Sciences, Durham, NC, ²Epidemiology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, NC
Background/Purpose: Early life trauma (ELT) and neighborhood deprivation (ND)—a measure of socioeconomic position (SEP)—represent two aspects of the early life social environment that can be…
Abstract Number: 2572 • ACR Convergence 2024
Biomarker-guided Treatment-and-stop-strategy for Recombinant IL-1Receptor Antagonist (Anakinra) in Patients with Systemic Juvenile Idiopathic Arthritis
Remco Erkens¹, Gerda Den Engelsman¹, Sytze De Roock¹, Dörte Hamann¹, Dieneke Schonenberg-Meinema², Merlijn van den Berg², Mariken Gruppen³, Wineke Armbrust⁴, Elizabeth Legger⁵, Sylvia Kamphuis⁶, Marleen Verkaaik⁷, Ellen Schatorjé⁸, Esther Hoppenreijs⁸, Thomas Vogl⁹, Johannes Roth⁹, Petra Hissink Muller¹⁰, Joost Swart¹, Marc Jansen¹, Jorg van Loosdregt¹¹ and Sebastiaan Vastert¹, ¹University Medical Center Utrecht, Utrecht, Netherlands, ²Amsterdam University Medical Center, Amsterdam, Netherlands, ³Amsterdam UMC, Amsterdam, Netherlands, ⁴University Medical Hospital Groningen, Groningen, Netherlands, ⁵University Medical Center Groningen, Groningen, Netherlands, ⁶Erasmus University Medical Center, Rotterdam, Netherlands, ⁷Erasmus Medical Center Rotterdam, Rotterdam, Netherlands, ⁸University Medical Center Radboud, Nijmegen, Nijmegen, Netherlands, ⁹University of Münster, Münster, Germany, ¹⁰Leiden University Medical Center, Leiden, Netherlands, ¹¹University Medical Center Utrecht, La Jolla, CA
Background/Purpose: Early initiation of treatment with the recombinant Interleukin 1 receptor antagonist (IL-1Ra), anakinra, in Still’s disease (SD), specifically systemic Juvenile Idiopathic Arthritis, patients is…
Abstract Number: 2566 • ACR Convergence 2024
Detrimental Effects of Proton Pump Inhibitors on Bone Mineral Density Are Not Mediated by Changes in Serum Calcium or Parathyroid Hormone in Patients with Inflammatory Rheumatic Diseases: A Cross-sectional Study
andriko Palmowski¹, Zhivana Boydzhieva², Paula Hoff³, Sandra Hermann³, burkhard Muche³, David Simon⁴, Gerhard Krönke³, Edgar Wiebe⁵ and FRANK HARTMUT DR. BUTTGEREIT⁵, ¹Charité - Universittsmedizin Berlin, Berlin, Germany, ²Charité Universittsmedizin, Berlin, Germany, ³Rheumatology, Charité, Berlin, Germany, ⁴Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany/ Department of Internal Medicine 3, University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany/Deutsches Zentrum für Immuntherapie (DZI), University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Berlin, Germany, ⁵Charité University Medicine Berlin, Berlin, Germany
Background/Purpose: In a previous study, we found daily proton pump inhibitor (PPI) intake to be associated with decreased bone mineral density in patients with inflammatory…
Abstract Number: 2553 • ACR Convergence 2024
Predictors of Biologic and Targeted Synthetic DMARD Initiation for Rheumatoid Arthritis Across Underserved Patient Groups: Insights from a National Cohort Study
Mark Russell¹, Mark Gibson², Benjamin Zuckerman¹, Kanta Kumar³, Shirish Dubey⁴, Maryam Adas², Edward Alveyn², Samir Patel¹, Zijing Yang¹, Katie Bechman², Elizabeth Price⁵, Sarah Gallagher⁶, Andrew Cope², Sam Norton¹ and James Galloway⁷, ¹King's College London, London, England, United Kingdom, ²King's College London, London, United Kingdom, ³University of Birmingham, Birmingham, United Kingdom, ⁴Oxford University Hospitals NHS FT, Oxford, United Kingdom, ⁵Great Western Hospital NHS Foundation Trust, Swindon, England, United Kingdom, ⁶British Society for Rheumatology, London, United Kingdom, ⁷Centre for Rheumatic Diseases, King's College London, London, United Kingdom
Background/Purpose: Quantifying healthcare inequality is essential to addressing the imbalance in outcomes attributable to age, gender, ethnicity and multimorbidity. In this study, we analysed differences…
Abstract Number: 2578 • ACR Convergence 2024
Safety, Biomarker Response, and Efficacy of E6742, a Dual Antagonist of Toll-Like Receptor 7 and 8, in a First-in-Patient, Randomized, Double-Blind, Phase1/2 Study in Systemic Lupus Erythematosus
Yoshiya Tanaka¹, Atsushi Kumanogoh², Tatsuya Atsumi³, Tomonori Ishii⁴, Fumitoshi Tago⁵, Mari Aoki⁵, Shintaro Yamamuro⁵, Keisuke Sakayori⁵, Kentaro Takahashi⁵ and Shizuo Akira⁶, ¹Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, ²Osaka University, Osaka, Japan, ³Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, Sapporo, Japan, ⁴Tohoku Medical and Pharmaceutical University / Department of Hematology and Rheumatology, sendai, Japan, ⁵Eisai Company, Ltd., Tokyo, Japan, ⁶Osaka University Immunology Frontier Research Center, Osaka, Japan
Background/Purpose: There is strong evidence for the relationship between Toll-like receptor (TLR)7/8 and systemic lupus erythematosus (SLE) pathophysiology. Dual inhibition of TLR7/8 will modulate innate…
Abstract Number: 2586 • ACR Convergence 2024
Results from the Biopsy Driven Ebio Study: Entheseal Tissue Signature in Response to IL-17 Blockade in Psoriatic Arthritis
Maria Gabriella Raimondo¹, Hashem Mohammadian², Stefano Alivernini³, Simon Rauber¹, Filippo Fagni⁴, Giulia Corte⁵, Koray Tascilar², Maria Antonietta D´Agostino⁶, Georg Schett⁷, Arnd Kleyer⁸ and Andreas Ramming¹, ¹Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Bayern, Germany, ²Department of Internal Medicine 3, Rheumatology & Immunology, Friedrich-Alexander-University (FAU) Erlangen-Nurnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ³Division of Rheumatology - Fondazione Policlinico Universitario A. Gemelli IRCCS - Università Cattolica del Sacro Cuore, Rome, Italy, Rome, Italy, ⁴Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, ⁵Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Bayern, Germany, ⁶Catholic University of Sacred Heart, Rome, Italy, Rome, Italy, ⁷Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ⁸Charité - Universittsmedizin Berlin, Erlangen, Germany
Background/Purpose: Enthesitis is considered to be an early event in psoriatic arthritis (PsA) course, representing a hallmark feature of the disease. So far, most of…
Abstract Number: 2581 • ACR Convergence 2024
Vunakizumab in Patients with Active Psoriatic Arthritis: A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study
Hejian Zou¹, Weiguo Wan², Yu Xue¹, Lingyun Sun³, Ning Zhang⁴, Haiying Chen⁵, Xiaofei Shi⁶, Shengyun Liu⁷, Lin Chen⁸, Xinmei Ma⁹, Hua Wei¹⁰, Zhenyu Jiang¹¹, Xiaomei Li¹², Hongtao Fan¹³, Hongbin Li¹⁴, Jingyang Li¹⁵, Rui Wu¹⁶, Guixiu Shi¹⁷, Jing Zhu¹⁸, Xiaodan Kong¹⁹, Yuewu Lu²⁰, Xiaojing Cui²¹, Qianning Zheng²¹, Xiaoyan Bai²² and Guangchao Dong²¹, ¹Department of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China, Shanghai, China (People's Republic), ²Huashan Hospital, Fudan University, Shanghai, China (People's Republic), ³Dept of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing Univ Medical School, Nanjing, CN, Nanjing, China (People's Republic), ⁴Shengjing Hospital Affiliated to China Medical University, Shenyang, China (People's Republic), ⁵The Third Hospital of Hebei Medical University, Shijiazhuang, China (People's Republic), ⁶The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China (People's Republic), ⁷The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China (People's Republic), ⁸Jilin Province People's Hospital, Changchun, China (People's Republic), ⁹Zaozhuang Municipal Hospital, Zaozhuang, China (People's Republic), ¹⁰Subei People's Hospital of Jiangsu Province, Yangzhou, China (People's Republic), ¹¹The First Hospital of Jilin University, Changchun, China (People's Republic), ¹²The First Affiliated Hospital of the University of Science and Technology of China, Hefei, China (People's Republic), ¹³The First People's Hospital of Yunnan Province, Kunming, China (People's Republic), ¹⁴Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China (People's Republic), ¹⁵Zhuzhou Central Hospital, Zhuzhou, China (People's Republic), ¹⁶The Tirst Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, China (People's Republic), ¹⁷The First Affilated Hospital of Xiamen University, Xiamen, China (People's Republic), ¹⁸Sichuan Provincial People's Hospital, Chengdu, China (People's Republic), ¹⁹The Second Affiliated Hospital of Dalian Medical University, Dalian, China (People's Republic), ²⁰BeiJing Chao-Yang Hospital, Capital Medical University, Beijing, China, ²¹Jiangsu Hengrui Pharmaceuticals Co., Ltd., Shanghai, China (People's Republic), ²²Jiangsu Hengrui Pharmaceuticals Co., Ltd., Beijing, China
Background/Purpose: Patients with psoriasis often develop psoriatic arthritis (PsA), a chronic systemic inflammatory disease with a severe clinical burden that impairs quality of life. In…
Abstract Number: 2599 • ACR Convergence 2024
Xist Deletion in B Cells Results in Systemic Lupus Erythematosus Phenotypes
Claudia Lovell¹, Nikhil Jiwrajka², Hayley Amerman³, Michael Cancro⁴ and Montserrat Anguera⁵, ¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²Hospital of the University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA, ⁴Perelman School of Medicine, Philadelphia, PA, ⁵University of Pennsylvania, Philadelphia, PA
Background/Purpose: Systemic lupus erythematosus (SLE) exhibits a strong female sex bias but the mechanisms underlying this bias are not well understood. Epidemiological studies demonstrate that…
Abstract Number: 2580 • ACR Convergence 2024
Safety and Efficacy of Subcutaneous Ianalumab (VAY736) for up to 68 Weeks in Patients with Systemic Lupus Erythematosus: Results from Phase 2 Study
Eduardo Mysler¹, Stanislav Ignatenko², Alexander Gordienko³, Josefina Cortés-Hernández⁴, Nancy Agmon-Levin⁵, Pongthorn Narongroeknawin⁶, Katarzyna Romanowska-Prochnicka⁷, Nan Shen⁸, Hana Ciferská⁹, Masanari Kodera¹⁰, James Cheng-Chung Wei¹¹, Piotr Leszczynski¹², Joung Liang Lan¹³, Rafał Wojciechowski¹⁴, Tunde Tarr¹⁵, Elena Vishneva¹⁶, Yi-Hsing Chen¹⁷, Yuko Kaneko¹⁸, Stephanie Finzel¹⁹, Alberta Hoi²⁰, Masato Okada²¹, Ajchara Koolvisoot²², Shin-Seok Lee²³, Lie Dai²⁴, Hiroshi Kaneko²⁵, Bernadette Rojkovich²⁶, Lingyun Sun²⁷, Eugeny Zotkin²⁸, Jean-François Viallard²⁹, Berta Paula Magallares³⁰, Tirtha Sengupta³¹, Carole Sips³², Carole Lau³³, Alexandre Avrameas³² and Stephen J Oliver³⁴, ¹Organizacion Medica de Investigacion, Buenos Aires, AR, Buenos Aires, Argentina, ²Charité Research Organisation, GmbH, Berlin, DE, Berlin, Germany, ³SM Kirov Military Medical Academy, St Petersburg, RU, St Petersburg, Russia, ⁴Hospital Universitario Vall d´Hebrón Hospitals, Barcelona, ES, Barcelona, Spain, ⁵Center for Autoimmune Disease, Sheba Medical Center, Tel Aviv University, Tel Aviv, IL, Tel Aviv, Israel, ⁶Rheumatic Disease Unit, Department of Internal Medicine, Phramongkutklao Hospital and College of Medicine, Bangkok, TH, Bankok, Thailand, ⁷Department of Systemic Connective Tissue Diseases, National Institute of Geriatrics, Rheumatology and Rehabilitation, Warsaw, PL, Warsaw, Poland, ⁸Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jaiotong University School of Medicine, Shanghai, CN, Shanghai, China (People's Republic), ⁹Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, CZ, Prague, Czech Republic, ¹⁰Department of Dermatology, Japan Community Healthcare Organization, Chukyo Hospital, Nagoya, JP, Nagoya, Japan, ¹¹Department of Rheumatology, Chung Shan Medical University Hospital, Taichung, TW, Taichung, Taiwan (Republic of China), ¹²Department of Internal Medicine, Poznan University of Medicine Sciences, Poznan, PL, Poznan, Poland, ¹³Rheumatology and Immunology Center, China Medical University Hospital, Taichung, TW, Taichung, Taiwan (Republic of China), ¹⁴Department of Rheumatology and Systemic Connective Tissue Diseases, University Hospital No. 2, Bydgoszcz, PL, Bydgoszcz, Poland, ¹⁵Division of Clinical Immunology, Faculty of Medicine, University of Debrecen, Debrecen, HU, Debrecen, Hungary, ¹⁶LLC Family Clinic, Yekaterinburg, RU, Yekaterinburg, Russia, ¹⁷Taichung Veterans General Hospital, Taichung, TW, Taichung, Taiwan (Republic of China), ¹⁸Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, JP, Shinjuku-ku, Tokyo, Japan, ¹⁹Department of Rheumatology and Clinical Immunology, University Medical Center Freiburg, Freiburg, DE, Freiburg im Breisgau, Germany, ²⁰Monash Health, Monash University, Melbourne, AU, Melbourne, Victoria, Australia, ²¹Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, JP, Tokyo, Japan, ²²Division of Rheumatology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, TH, Bangkok, Thailand, ²³Division of Rheumatology, Department of Internal Medicine, Chonnam National University Medical School and Hospital, Gwangju, KR, Gwangju, Republic of Korea, ²⁴Department of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, CN, Guangzhou, China (People's Republic), ²⁵Division of Rheumatic Disease, National Center for Global Health and Medicine, Tokyo, JP, Tokyo, Japan, ²⁶Department of Rheumatology and Physiotherapy, Polyclinic of the Hospitaller Brothers of St. John of God, Semmelweis University, Budapest, HU, Budapest, Hungary, ²⁷Dept of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing Univ Medical School, Nanjing, CN, Nanjing, China (People's Republic), ²⁸V A Nasonova Research Institute of Rheumatology, Moscow, RU, Moscow, Russia, ²⁹CHU de Bordeaux, Hôpital Haut-Lévêque, Pessac, FR, Bordeaux, France, ³⁰Dept of Rheumatology, Hospital de la Santa Creu I Sant Pau, Barcelona, ES, Barcelona, Spain, ³¹Novartis Pharma India, Hyderabad, IN, Hyderabad, India, ³²Novartis Pharma AG, Basel, CH, Basel, Switzerland, ³³Novartis Pharma, East Hanover, NJ, USA, East Hanover, ³⁴Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Ianalumab (VAY736) is an afucosylated, fully human IgG1 monoclonal antibody with a dual mechanism of action of enhanced B-cell depletion through antibody-dependent cellular cytotoxicity…
Abstract Number: 2588 • ACR Convergence 2024
Examining the Influence of Socioeconomic Status on Osteoarthritis Prevalence and Risk Factors Among New York Residents
Titilayo Adeniran¹, David Cecil² and Ahinee Amamoo³, ¹Hospital for Special Surgery (HSS), New York, NY, ²Samford University, Birmingham, ³Samford University, Birmingham, AL
Background/Purpose: Osteoarthritis (OA) is a chronic, progressive condition affecting the musculoskeletal system, significantly impacting the quality of life and mobility of millions worldwide. It is…
Abstract Number: 2591 • ACR Convergence 2024
Lupus-Related Reproductive Health Experiences and Needs of Women of Childbearing Age: A Qualitative Study
Yasmine Shakur¹, Charmayne M. Dunlop-Thomas², S. Sam Lim¹ and Subasri Narasimhan¹, ¹Emory University, Atlanta, GA, ²Emory University School of Medicine, Department of Medicine, Division of Rheumatology, Atlanta, GA
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune condition that primarily affects women of childbearing age, with many patients being diagnosed during puberty. Contraception…
Abstract Number: 2609 • ACR Convergence 2024
Drivers of Infliximab Biosimilar Uptake: A Comparative Analysis of New Biosimilar Initiations versus Switching in a National Rheumatology Registry
Eric Roberts¹, Nick Bansback², Chien-Wen Tseng³, Steve Shiboski⁴, Jing Li⁵, Gabriela Schmajuk⁶ and Jinoos Yazdany⁷, ¹University of California, San Francisco, SF, CA, ²University of British Columbia, Vancouver, BC, Canada, ³University of Hawai'i John A. Burns School of Medicine, Honolulu, ⁴University of California, San Francisco, San Francisco, ⁵University of California, San Francisco, San Francisco, CA, ⁶UCSF / SFVA, San Francisco, CA, ⁷UCSF, San Francisco, CA
Background/Purpose: Biosimilars hold promise for reducing pharmaceutical expenditures, however uptake has lagged. We analyzed the variability in new biosimilar starts and switching from bio-originator infliximab…
Abstract Number: 2610 • ACR Convergence 2024
Treatment Concordance of Asynchronous Virtual Visits Compared to Traditional In-person Visits in Patients with Rheumatoid Arthritis: Results of the Prospective, Multi-center, Randomized Controlled TELERA Trial
Johannes Knitza¹, Johanna Mucke², Manuel Grahammer³, Sebastian Kuhn¹, Nicolas Vuillerme⁴, Felix Muehlensiepen⁵, Gerhard Krönke⁶, Georg Schett⁷, Ann-Christin Pecher⁸ and Martin Krusche⁹, and the TELERA Study Group, ¹Institute for Digital Medicine, University Hospital Marburg, Philipps-University Marburg, Marburg, Germany, Marburg, Germany, ²Heinrich-Heine-University, Duesseldorf, Germany, ³ABATON, Berlin, Germany, ⁴AGEIS, Université Grenoble Alpes, 38000 Grenoble, France, Grenoble, France, ⁵Center for Health Services Research, Faculty of Health Sciences Brandenburg, Brandenburg Medical School Theodor Fontane, Rüdersdorf, Germany, Berlin, Germany, ⁶Rheumatology, Charité, Berlin, Germany, ⁷Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ⁸Interdisciplinary Center of Rheumatic Diseases (INDIRA), University Hospital Tuebingen, Tuebingen, Germany, Tübingen, Germany, ⁹III Department of Medicine, Division of Rheumatology and Systemic Inflammatory Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Hamburg, Germany
Background/Purpose: Access to rheumatology care is becoming increasingly limited, necessitating a re-evaluation of patient pathways. The objective of this study was to evaluate a new…
Abstract Number: 2608 • ACR Convergence 2024
Evolution of Rheumatoid Arthritis Pharmacotherapy: A Ten-Year Analysis of Biologic and Targeted Synthetic DMARD Use and Its Predictors in a National Sample of Rheumatology Practices
Jing Li¹, Gabriela Schmajuk² and Jinoos Yazdany³, ¹University of California, San Francisco, San Francisco, CA, ²UCSF / SFVA, San Francisco, CA, ³UCSF, San Francisco, CA
Background/Purpose: The last decade has seen dramatic shifts in pharmacotherapy for rheumatoid arthritis (RA) with the increasing availability of biologic and targeted synthetic DMARDs (b/tsDMARDs).…
Abstract Number: 2596 • ACR Convergence 2024
Clock Gene Bmal1 Contributes to Inflammation via Phosphorylation of NF-κB/p65 in RA-FLS
Hikari Tsukamoto¹, Kenta Kaneshiro¹, Kohsuke Yoshida¹, Koji Tateishi², Yasuhiro Terashima², Nao Shibanuma³, Yoshitada Sakai⁴ and Akira Hashiramoto¹, ¹Kobe University Graduate School of Health Sciences, Kobe, Hyogo, Japan, ²Hakuhokai Kakogawa Hospital, Kakogawa, Hyogo, Japan, ³Kobe Kaisei Hospital, Kobe, Hyogo, Japan, ⁴Kobe University Graduate School of Medicine, Kobe, Hyogo, Japan
Background/Purpose: Inflammatory cytokines such as TNF-α, IL-6, and IFN-γ show their peaks at midnight in sera of patients with rheumatoid arthritis (RA), which is thought…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].